Article Text

PDF
Original article
Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile
  1. Morten K Jensen1,
  2. Christian Prinz2,
  3. Dieter Horstkotte2,
  4. Frank van Buuren2,
  5. Thomas Bitter2,
  6. Lothar Faber2,
  7. Henning Bundgaard1
  1. 1Department of Cardiology, The Heart Center, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
  2. 2Department for Cardiology, Heart Center North Rhine Westfalia, Ruhr-University Bochum, Bad Oeynhausen, Germany
  1. Correspondence to Dr Morten Kvistholm Jensen, Department of Cardiology 2142, The Heart Center, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen 2100, Denmark; mortenjensen{at}dadlnet.dk

Abstract

Background The infarction induced by alcohol septal ablation (ASA) may predispose to arrhythmia and sudden cardiac death (SCD).

Objective To assess survival, incidence of SCD after ASA and effects of ASA on the traditional risk factors (RFs) for SCD.

Design An observational cohort-study (follow-up 8.4±4 years).

Setting A dual-centre cohort.

Patients 470 consecutive patients (age 56±14 years) with obstructive hypertrophic cardiomyopathy (HCM) (1996–2010).

Interventions Clinically applied echo-contrast-guided ASA treatments.

Main outcome measures All-cause mortality, SCD and RFs for SCD before and after ASA.

Results The 10-year survival was 88% (annual all-cause death rate 1.2%) after ASA compared with 84% (p=0.06) in a matched background population. The 10-year survival free of SCD was 95% (annual SCD rate 0.5%). ASA reduced the prevalence of abnormal blood pressure response (from 23% to 9%, p<0.001), syncope (26% to 2%, p<0.001), non-sustained ventricular tachycardia (NSVT) (23% to 17%, p<0.05) and maximal wall thickness ≥30 mm (7% to 2%, p<0.001). There was a family history of SCD in 19% of the patients. The proportion of patients at high risk—that is, two or more RFs (n=89), was reduced from 25% to 8% (p<0.001). A RF score ≥2 before ASA was not associated with SCD (n=361, p=0.31).

Conclusions Survival in ASA-treated patients was similar to that in the background population. The number of RFs, including the prevalence of NSVT, was markedly reduced by ASA and the incidence of SCD was correspondingly low. Thus, clinically applied ASA was safe.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.